Inflammatory biomarkers of coronary atheromatous plaque vulnerability

Panminerva Medica

Volumn 47, Issue 2, 2005, Pages 81-91

  Avanzas, P ^a   Arroyo Espliguero, R ^b   Garcia Moll, X ^c   Kaski, J C ^c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Biological markers; Coronary disease; Inflammation

Indexed keywords

BIOLOGICAL MARKER;

CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; IMMUNOLOGY; PATHOLOGY; REVIEW; VASCULITIS;

BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; HUMANS; VASCULITIS;

EID: 27744556718     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004;110:1747-53.
3. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
4. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72.
5. Shah PK. Plaque disruption and thrombosis. Potential role of inflammation and infection. Cardiol Clin 1999;17:271-81.
6. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999;130:933-7.
7. Kaski JC, Chester MR, Chen L, Katritsis D. Rapid angiographic progression of coronary artery disease in patients with angina pectoris. The role of complex stenosis morphology. Circulation 1995;92:2058-65.
8. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79:733-43.
9. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol 1994;23:809-13.
10. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003;108:1664-72.
11. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-71.
12. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90:775-8.
13. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92:1565-9.
14. Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler.Thromb Vasc Biol 1997;17:2200-8.
15. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
16. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
17. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J.Clin.Invest 1994;94:2493-503.
18. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93:1354-63.
19. Kridel SJ, Sawai H, Ratnikov BI, Chen EI, Li W, Godzik A et al. A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. J Biol Chem 2002;277:23788-93.
20. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999;274:11924-9.
21. Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 1992;12:206-11.
22. Caligiuri G, Paulsson G, Nicoletti A, Maseri A, Hansson GK. Evidence for antigen-driven T-cell response in unstable angina. Circulation 2000;102:1114-9.
23. Liuzzo G, Kopecky SL, Frye RL, O'Fallon WM, Maseri A, Goronzy JJ et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999;100:2135-9.
24. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.
25. Arroyo-Espliguero R, Avanzas P, Jeffery S, Kaski JC. CD14 and toll-like receptor 4: a link between infection and acute coronary events? Heart 2004;90:983-8.
26. Chandra HR, Choudhary N, O'Neill C, Boura J, Timmis GC, O'Neill WW. Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS). Am J Cardiol 2001;88:214-8.
27. Arroyo-Espliguero R, El Sharnouby K, Vazquez-Rey E, Kalidas K, Jeffery S, Kaski JC. CD14 C(-260)T promoter polymorphism and prevalence of acute coronary syndromes. Int J Cardiol 2005;98:307-12.
28. Liuzzo G, Angiolillo DJ, Buffon A, Rizzello V, Colizzi C, Ginnetti F et al. Enhanced response of blood monocytes to in vitro lipopolysaccharide- challenge in patients with recurrent unstable angina. Circulation 2001;103:2236-41.
29. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999;283:1335-9.
30. Biasucci LM, Liuzzo G, Ciervo A, Petrucca A, Piro M, Angiolillo DJ et al. Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation 2003;107:3015-7.
31. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000;343:915-22.
32. Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002;106:804-8.
33. Asakura M, Ueda Y, Yamaguchi O, Adachi T, Hirayama A, Hori M et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol 2001;37:1284-8.
34. Arroyo-Espliguero R, Avanzas P, Cosin-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004;25:401-8.
35. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Aldama G, Pizzi C, Quiles J et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 2004;90:847-52.
36. Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol 2000;35:956-62.
37. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12.
38. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002;106:2894-900.
39. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988;78(5 Pt 1):1157-66.
40. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996;94:2013-20.
41. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004;116 Suppl 6A:9S-16S.
42. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
43. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
44. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997;96:4204-10.
45. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
46. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
47. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
48. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J.Am.Coll.Cardiol 1998;31:1460-5.
49. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J.Am.Coll.Cardiol 2000;35:1535-42.
50. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139-47.
51. Ferreiros ER, Boissonnet CP, Pizarro R, Merletti PF, Corrado G, Cagide A et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999;100:1958-63.
52. Yen ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001;104:974-5.
53. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.
54. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002;105:2019-23.
55. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
56. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001;103:1194-7.
57. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4.
58. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.
59. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999;42:23-30.
60. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler. Thromb Vasc Biol 1998;18:1386-92.
61. Katritsis D, Korovesis S, Giazitzoglou E, Parissis J, Kalivas P, Webb-Peploe MM et al. C-Reactive protein concentrations and angiographic characteristics of coronary lesions. Clin Chem 2001;47:882-6.
62. Arroyo-Espliguero R, Avanzas P, Kaski JC. [Atherosclerotic coronary artery disease: usefulness of C-reactive protein for the identification of the vulnerable plaque and the vulnerable patient]. Rev Esp Cardiol 2004;57:375-8.
63. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
64. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
65. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003;108:161-5.
66. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, III, Criqui M et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
67. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
68. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160:310-6.
69. Schobersberger W, Hoffmann G, Grote J, Wachter H, Fuchs D. Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cells. FEBS Lett. 1995;377:461-4.
70. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Schmidt K et al. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J Biol Chem 1993;268:1842-6.
71. Wirleitner B, Baier-Bitterlich G, Hoffmann G, Schobersberger W, Wachter H, Fuchs D. Neopterin derivatives to activate NF-kappa B. Free Radic Biol Med 1997;23:177-9.
72. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
73. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996;97:1715-22.
74. Thurberg BL, Collins T. The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 1998;9:387-96.
75. Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Waeg G et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991;89:203-8.
76. Weiss G, Willeit J, Kiechl S, Fuchs D, Jarosch E, Oberhollenzer F et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis 1994;106:263-71.
77. Anwaar I, Gottsater A, Lindgarde F, Mattiasson I. Increasing plasma neopterin and persistent plasma endothelin during follow-up after acute cerebral ischemia. Angiology 1999;50:1-8.
78. Gupta S, Fredericks S, Schwartzman RA, Holt DW, Kaski JC. Serum neopterin in acute coronary syndromes. Lancet 1997;349:1252-3.
79. Schumacher M, Halwachs G, Tatzber F, Fruhwald FM, Zweiker R, Watzinger N et al. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol 1997;30:703-7.
80. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999;19:2355-63.
81. van Haelst PL, Liem A, van Boven AJ, Veeger NJ, van Veldhuisen DJ, Tervaert JW et al. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol 2003;92:1201-3.
82. Garcia-Moll X, Cole D, Zouridakis E, Kaski JC. Increased serum neopterin: a marker of coronary artery disease activity in women. Heart 2000;83:346-50.
83. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005;26:457-63.
84. van Haelst PL, van Doormaal JJ, May JF, Gans RO, Crijns HJ, Cohen Tervaert JW. Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Eur J Intern Med 2001;12:503-9.
85. Boldt HB, Overgaard MT, Laursen LS, Weyer K, Sottrup-Jensen L, Oxvig C. Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin. Biochem J 2001;358:359-67.
86. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR, Jr. et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-9.
87. Bayes-Genis A, Schwartz RS, Lewis DA, Overgaard MT, Christiansen M, Oxvig C et al. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vasc Biol 2001;21:335-41.
88. Cosin-Sales J, Christiansen M, Kaminski P, Oxvig C, Overgaard MT, Cole D et al. Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation 2004;109:1724-8.
89. Khosravi J, Diamandi A, Krishna RG, Bodani U, Mistry J, Khaja N. Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease. Clin Biochem 2002;35:531-8.
90. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999;96:3149-53.
91. Laursen LS, Overgaard MT, Soe R, Boldt HB, Sottrup-Jensen L, Giudice LC et al. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett. 2001;504:36-40.
92. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res 2000;86:125-30.
93. Hochberg Z, Hertz P, Maor G, Oiknine J, Aviram M. Growth hormone and insulin-like growth factor-I increase macrophage uptake and degradation of low density lipoprotein. Endocrinology 1992;131:430-5.
94. Renier G, Clement I, Desfaits AC, Lambert A. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-alpha production. Endocrinology 1996;137:4611-8.
95. Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001;39:380-4.
96. Qin QP, Laitinen P, Majamaa-Voltti K, Eriksson S, Kumpula EK, Pettersson K. Release patterns of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand Cardiovasc J 2002;36:358-61.
97. Oxvig C, Sand O, Kristensen T, Gleich GJ, Sottrup-Jensen L. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J Biol Chem 1993;268:12243-6.
98. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-9.
99. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 1990;265:9682-7.
100. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem.Biophys. Res Commun 1999;261:511-4.
101. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38:1302-6.
102. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
103. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003;41(4 Suppl S):37S-42S.
104. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-7.
105. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-40.
106. Kaski JC, Cruz-Fernandez JM, Fernandez-Berges D, Garcia-Moll X, Martin JL, Mostaza J et al. [Inflammation markers and risk stratification in patients with acute coronary syndromes: design of the SIE-STA Study (Systemic Inflammation Evaluation in Patients with non-ST segment elevation Acute coronary syndromes)]. Rev Esp Cardiol 2003;56:389-95.